Cholesgen (Shanghai) Co.Ltd.

Cholesgen conclut avec AstraZeneca un accord de collaboration pour la découverte de médicaments et un accord d’option de licence pour l’hypercholestérolémie USA – Français USA – español USA – English USA – English USA – Deutsch

by

SHANGHAI, 16 juin 2023 /PRNewswire/ — Cholesgen (Shanghai) Co.Ltd. (Cholesgen) a annoncé aujourd’hui une nouvelle collaboration passionnante avec AstraZeneca pour faire progresser la recherche et le développement sur l’hypercholestérolémie et les maladies métaboliques connexes. Cette collaboration de trois ans vise à valider les cibles génétiques des médicaments et à faire progresser les molécules thérapeutiques vers … Read more

Cholesgen to enter into a drug discovery collaboration and licensing option agreement in hypercholesterolemia with AstraZeneca

by

SHANGHAI, June 16, 2023 /PRNewswire/ — Cholesgen (Shanghai) Co.Ltd. (‘Cholesgen’) today announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca. This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint research effort will leverage complementary strengths and focus on selected targets … Read more

Cholesgen to enter into a drug discovery collaboration and licensing option agreement in hypercholesterolemia with AstraZeneca

by

SHANGHAI, June 16, 2023 /PRNewswire/ — Cholesgen (Shanghai) Co.Ltd. (‘Cholesgen’) today announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca. This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint research effort will leverage complementary strengths and focus on selected targets … Read more